STENTYS reports significant revenue increase in the 1st quarter of 2011

STENTYS (FR0010949404 – STNT), a medical technology company that markets a new generation of innovative stents to treat acute myocardial infarction, today reported its revenues for the 1st quarter to 31 March 2011.

• Quarterly revenues*

<table>
<thead>
<tr>
<th>€ thousands</th>
<th>Q1 2011</th>
<th>Q4 2010</th>
<th>Δ %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>251.4</td>
<td>145.9</td>
<td>+72.3%</td>
</tr>
</tbody>
</table>

*The company did not publish quarterly financial statements prior to its IPO; STENTYS began to market its products in the first half of 2010. 1st quarter 2011 revenues have not been audited.

Revenues totalled €251.4 thousand over the 1st quarter of 2011, at the level of the figure for the entire second half of 2010 (€233.4 thousand). Compared to the 4th quarter of 2010, revenues were up +72.3%, resulting from the acceleration of sales in countries in which STENTYS stents were already marketed in 2010, i.e. the Netherlands and Germany.

This level of sales is in line with the Company’s expectations.

Gonzague Issenmann, CEO and co-founder of Stentys, concluded: “The rapid increase of our sales reflects the good execution of our business plan, in line with our expectations. We are continuing to start the marketing of our products in new countries while pursuing our clinical trials according to our controlled release strategy. We are extremely confident that we will continue to record solid growth in revenues throughout 2011.”

About STENTYS:

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.


Next press release:

Revenue for the 2nd quarter and 1st half of 2011 will be published on 26 July 2011, after market.

Stentys
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Financial Communication / Investor & Press Relations
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
stentys@newcap.fr

STENTYS is listed on Compartiment C of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT